Navigation Links
JHP Pharmaceuticals and Putney Inc. Announce Multi-Year Contract Manufacturing Agreement
Date:1/27/2011

PARSIPPANY, N.J., Jan. 27, 2011 /PRNewswire/ -- JHP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectable products announced today that it has entered into a multi-year contract with Putney, Inc., a well-established and growing provider of veterinary pharmaceutical products. JHP will be responsible for manufacturing and supply of a lyophilized veterinary product.

Jean Hoffman, CEO and founder of Putney said, "We are pleased to partner with JHP Pharmaceuticals in the manufacture and supply of this significant product in veterinary healthcare."

Commenting on JHP's selection for this multi-year manufacturing contract, Stuart Hinchen president and cofounder of JHP stated, "We are very pleased that JHP was chosen by Putney. Our experienced staff, customer centric approach and cGMP compliance record will allow us to effectively serve this important customer."

Hinchen also noted, "As part of our ongoing investment in our Rochester facility, we are completing the installation and qualification of a new 240 sq. ft. lyophilizer. The new lyophilizer and recent agreements demonstrate our steady growth in both number of contract customers and facility capabilities. The Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing both clinical and commercial products.

Management at both companies sees this agreement as a positive cooperation focused on quality-driven pharmaceutical products improving patient health.

About JHP Pharmaceuticals, LLCJHP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectables, biologics, vaccines, ophthalmics and otics for large and small pharmaceutical and biotech organizations.

JHP's sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. The production facility utilizes three high-speed filling lines, four lyophilizers and a clinical fill line. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.

JHP has the capability to manufacture small-scale clinical through large-scale commercial products. JHP employs more than 330 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas. For more information, please visit www.jhppharma.com.

About Putney Inc.Putney is a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney's reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, and supports pet owners, helping them afford to comply with veterinary recommendations. Putney's ongoing investment in research and development is focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Learn more at www.putneyvet.com.Contact:Dan Leone973.658.3559Bill Conway877.906.7556jhpcontractservices@jhppharma.com
'/>"/>

SOURCE JHP Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
2. Amylin Pharmaceuticals Reports 2010 Financial Results
3. Prolong Pharmaceuticals Leases 24,000-Square-Foot Manufacturing Facility, Adds Facilities Veteran to Executive Team
4. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
5. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
6. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
7. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
10. Federal Government Obtains Permanent Injunction Against Deltex Pharmaceuticals Inc.
11. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... BioSciences, Inc. (NASDAQ: SGMO ), the leader ... quarter and full year 2015 financial results and ... editing," said Edward Lanphier, Sangamo,s president and chief ... leads the therapeutic genome editing field and we ... our ground-breaking genome editing programs through IND enabling ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
(Date:2/9/2016)... --  AllCare Plus Pharmacy announced today that it ... ® for Home Care Accreditation by ... Seal of Approval ® is a symbol of ... and effective care.  --> ... on-site survey in January 2016. The survey reflected compliance ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... It’s that time of year when ... president of the Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and ... goals are cast aside. , That’s why one of her first decisions when her ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... businesses recover after a disaster, announced today the acquisition of Hawaii DKI. Hawaii ... , “Investing in like-minded companies who excel at service and response ...
(Date:2/9/2016)... MA (PRWEB) , ... February 09, 2016 , ... ... (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for a ... services covered in the report, Evaluation of the 2015 Fee Schedule Rates ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), ... the ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient ... , “Since our Pay It Forward program began, we are proud to ...
(Date:2/9/2016)... ... 2016 , ... The Journal of Pain Research has published the ... , As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention ... pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the ...
Breaking Medicine News(10 mins):